Phase 3 Chronic Kidney Disease Trial, Recruiting
Who may be able to join
AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI
Who might be able to join this trial:
- People who are fluent in English and can understand and agree to the study terms in writing
- People who have end-stage kidney disease and are listed to receive their first kidney transplant (a single kidney, not a second transplant)
- People who are willing to follow all study requirements and have signed the official consent form
- Women who are able to become pregnant must agree to use two different medically approved forms of contraception throughout the study and for at least one year after the treatment infusion
Who may not be able to join:
- People who have previously had an organ, tissue, or cell transplant
- People who are allergic to the medications Tacrolimus or MMF (also called Cellcept)
- People who regularly use blood-thinning medications
- People who have a history of long-term use of steroid medications (such as prednisone), other immune-suppressing drugs, or biologic medications taken for serious inflammatory conditions
- People who currently have a significant or active infection
- People who have been diagnosed with HIV, Hepatitis B or C, Herpes simplex virus, Varicella-Zoster virus, or Epstein-Barr virus
- People who have had cancer within the past three years
- People who have taken part in another study involving an experimental drug within the last 12 months
- People who have a history of slow or abnormal wound healing
- People who are currently pregnant or breastfeeding
- People who have had a blood transfusion within the past three months
- People who have recently received or are planning to receive certain live vaccines, including nasal flu spray, measles, mumps, rubella, oral polio, yellow fever, or chickenpox vaccines
- People who are unable or unwilling to follow the study's procedures and requirements
- People who are currently taking anticoagulation (blood-thinning) medication (confirm with trial site, as this may overlap with the earlier blood thinner criterion)
Important: Always verify eligibility with the trial site directly before applying.
Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.
Contact this trial
Principal Investigator: Roberto Gedaly, MD, University of Kentucky
Phone: 8592579443
Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.
GP referral letter
Print a one-page summary to share with your doctor.
Trial details
Where this trial is recruiting
Primary endpoints
1. Change in the percentage of donor specific antibodies; Changes in the percentage of blood immunologic markers
Can't join this trial?
Data last synced from ClinicalTrials.gov: 16 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.